An immunologic case study of acute encephalitis with refractory, repetitive partial seizures

Wakamoto, Hiroyuki; Takahashi, Yukitoshi; Ebihara, Tomohiro; Okamoto, Katsushi; Hayashi, Masatoshi; Ichiyama, Takashi; Ishii, Eiichi

doi:10.1016/j.braindev.2011.12.007

Cited by 16 publications

(31 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 21 articles included in the review, 20 were original studies, [15][16][17][18][19][20][21][22][23][24][25][26][28][29][30][31][32][33][34][35] with one companion abstract publication identified. 27 The companion abstract was included for completeness 27 and was not included for the rest of the review to avoid duplication of patient data.…”

Section: Resultsmentioning

confidence: 99%

“…27 The companion abstract was included for completeness 27 and was not included for the rest of the review to avoid duplication of patient data. There were 15 original retrospective studies 15,16,18,20,21,[23][24][25][26]28,30,[32][33][34][35] and five prospective studies. 17,19,22,29,31 Within the retrospective studies, 12 were retrospective case series 15,16,18,20,21,24,26,28,30,32,34,35 and the remaining three were retrospective case reports.…”

Section: Resultsmentioning

confidence: 99%

“…15,16,18,20,21,[23][24][25][26]28,30,[32][33][34][35] Within these 15 studies, one used bolus dosing of lidocaine in isolation, 15 with a dose of 100 mg intravenously once.…”

Section: Lidocaine Treatment Characteristicsmentioning

confidence: 99%

“…20,24,32 Finally, four studies failed to document the details of lidocaine dosing and administration. 18,30,33,35 Lidocaine treatment characteristics can be seen in Table 2.…”

Section: Lidocaine Treatment Characteristicsmentioning

confidence: 99%

“…17,19,22,29,31 Fifteen studies represented Oxford level 4 evidence for lidocaine administration in pediatric SE/ RSE. 15,16,18,20,1,[23][24][25][26]27,28,30,[32][33][34][35] Two of the 20 studies met GRADE B level of evidence, 19,29 three met GRADE C evidence, 17,22,31 whereas the remaining 15 met GRADE D level of evidence. 15,16,18,20,1,[23][24][25][26]27,28,30,[32][33][34][35] Summary of the level of evidence can be seen in Table 3.…”

Section: Level Of Evidence For Lidocainementioning

confidence: 99%

See 4 more Smart Citations

Lidocaine for Status Epilepticus in Pediatrics

Zeiler

Teitelbaum

et al. 2015

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Background: Our goal was to perform a systematic review of the literature on the use of intravenous lidocaine in pediatrics for status epilepticus (SE) and refractory status epilepticus (RSE) to determine its impact on seizure control. Methods: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (inception to November 2014), and gray literature were searched. The strength of evidence was adjudicated using both the Oxford and Grading of Recommendations Assessment, Development, and Evaluation methodologies by two independent reviewers. Results: Overall, 20 original studies were identified, with 19 manuscripts and one meeting abstract. Two hundred and thirty-five pediatric patients were treated for 252 episodes of SE/RSE. Patients had varying numbers of antiepileptic drugs (two to eight) on board before lidocaine therapy. During 20 of the 252 (7.9%) episodes of SE/RSE, phenytoin was on board. The dose regimen of lidocaine varied, with some using bolus dosing alone; others used a combination of bolus and infusion therapy. Overall, 60.0% of seizures responded to lidocaine, with complete cessation and greater than 50% reduction seen in 57.6% and 12.3%, respectively. Patient outcomes were sparingly reported. Conclusions: There currently exists Oxford level 2b, Grading of Recommendations Assessment Developement, and Evaluation C evidence to support the consideration of lidocaine for SE and RSE in the pediatric population. Further prospective studies of lidocaine administration in this setting are warranted.RÉSUMÉ: Traitement de l'état de mal épileptique par la lidocaïne en pédiatrie. Contexte : Nous avons effectué une revue systématique de la littérature à propos de l'utilisation de la lidocaïne par voie intraveineuse chez des enfants en état de mal épileptique (ÉMÉ) ou d'ÉMÉ résistant au traitement (ÉMÉR) afin de déterminer son impact sur le contrôle de l'ÉMÉ. Méthode : Nous avons recherché tous les articles sur ce sujet indexés dans MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (du début jusqu' à novembre 2014) ainsi que la documentation parallèle. Deux réviseurs indépendants ont utilisé l'Oxford and Grading of Recommendations Assessment, Development and Evaluation pour évaluer la qualité des études. Résultats : En tout, 20 études originales ont été identifiées, dont 19 manuscrits et un résumé. Deux cent trente-cinq patients d'âge pédiatrique ont ainsi été traités au cours de 252 épisodes d'ÉMÉ/ÉMÉR. Les patients recevaient plusieurs médicaments antiépileptiques (de 2 à 8) avant le traitement par la lidocaïne. Au cours de 20 des 252 épisodes d'ÉMÉ/ÉMÉR (7,9%), le patient recevait de la phénytoïne. La dose de lidocaïne était variable : certains ont reçu seulement un bolus alors que d'autres ont reçu la lidocaïne en bolus et en perfusion. En tout, 60% des crises ont répondu à la lidocaïne avec arrêt complet de la crise chez 57,6% des...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…15,16,18,20,21,[23][24][25][26]28,30,[32][33][34][35] Within these 15 studies, one used bolus dosing of lidocaine in isolation, 15 with a dose of 100 mg intravenously once.…”

Section: Lidocaine Treatment Characteristicsmentioning

confidence: 99%

“…20,24,32 Finally, four studies failed to document the details of lidocaine dosing and administration. 18,30,33,35 Lidocaine treatment characteristics can be seen in Table 2.…”

Section: Lidocaine Treatment Characteristicsmentioning

confidence: 99%